Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, Järvenpää S, Hannonen P, Leirisalo-Repo M, Blåfield H, Puolakka K, Karjalainen A, Möttönen T; FIN-RACo Trial Group. Rantalaiho V, et al. Among authors: karjalainen a. Arthritis Res Ther. 2010;12(3):R122. doi: 10.1186/ar3060. Epub 2010 Jun 24. Arthritis Res Ther. 2010. PMID: 20576092 Free PMC article. Clinical Trial.
Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.
Karstila KL, Rantalaiho VM, Mustonen JT, Möttönen TT, Hannonen PJ, Leirisalo-Repo M, Kaipiainen-Seppänen OA, Karjalainen AH, Korpela MM; FIN-RACo Trial Group. Karstila KL, et al. Among authors: karjalainen ah. Clin Exp Rheumatol. 2010 Jan-Feb;28(1):73-8. Clin Exp Rheumatol. 2010. PMID: 20346242 Clinical Trial.
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T; NEO-RACo Study Group. Leirisalo-Repo M, et al. Among authors: karjalainen a. Ann Rheum Dis. 2013 Jun;72(6):851-7. doi: 10.1136/annrheumdis-2012-201365. Epub 2012 Jun 30. Ann Rheum Dis. 2013. PMID: 22753402 Clinical Trial.
Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M; NEO-RACo Study Group. Rantalaiho V, et al. Among authors: karjalainen a. Ann Rheum Dis. 2014 Nov;73(11):1954-61. doi: 10.1136/annrheumdis-2013-203497. Epub 2013 Aug 1. Ann Rheum Dis. 2014. PMID: 23908187 Clinical Trial.
Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.
Rantalaiho V, Kautiainen H, Järvenpää S, Korpela M, Malmi T, Hannonen P, Kaipiainen-Seppänen O, Yli-Kerttula T, Möttönen T, Mustila A, Karjalainen A, Paimela L, Uutela T, Leirisalo-Repo M; NEO-RACo Study Group. Rantalaiho V, et al. Among authors: karjalainen a. J Rheumatol. 2014 Dec;41(12):2379-85. doi: 10.3899/jrheum.140267. Epub 2014 Oct 1. J Rheumatol. 2014. PMID: 25274892 Clinical Trial.
Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study.
Sandström T, Rantalaiho V, Yli-Kerttula T, Kautiainen H, Malmi T, Karjalainen A, Uusitalo T, Julkunen H, Kaipiainen-Seppänen O, Paimela L, Puolakka K, Uutela T, Möttönen T, Hannonen P, Leirisalo-Repo M, Laasonen L, Kauppi M; NEO-RACo Study Group. Sandström T, et al. Among authors: karjalainen a. J Rheumatol. 2020 Aug 1;47(8):1160-1164. doi: 10.3899/jrheum.190139. Epub 2019 Nov 15. J Rheumatol. 2020. PMID: 31732558 Clinical Trial.
Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.
Kuusalo L, Puolakka K, Kautiainen H, Blåfield H, Eklund KK, Ilva K, Kaipiainen-Seppänen O, Karjalainen A, Korpela M, Valleala H, Leirisalo-Repo M, Rantalaiho V; Neo-RACo Study Group. Kuusalo L, et al. Among authors: karjalainen a. Scand J Rheumatol. 2015;44(6):449-55. doi: 10.3109/03009742.2015.1043142. Epub 2015 Aug 31. Scand J Rheumatol. 2015. PMID: 26324784 Clinical Trial.
233 results